lantheusmedicalimaging

A Phase 4 Open-Label Multicenter Study of PYLARIFY® PET/CT or PET/MRI in Men With Newly Diagnosed Favorable Intermediate Risk (FIR) Prostate Cancer

Description:

The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer.

Contacts:

Senior Clinical Trial Manager

pyl4301studyinfo@lantheus.com

1(646) 975-2540

Patient Education


Patient Education Not Yet Provided

Publications


Publications Not Yet Provided

Locations


🇺🇸 United States

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

Principal Investigator

Gary Ulaner, MD

Johns Hopkins University

Baltimore, Maryland 21287, United States

University of California, San Francisco

San Francisco, California 94158, United States

Tower Urology

Los Angeles, California 90048, United States

BAMF Health

Grand Rapids, Michigan 49503, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

University of Alabama at Birmingham Hospital

Birmingham, Alabama 35249, United States

XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468